文献速递胸部肿瘤

八万例肺癌患者分子图谱分析:跨组织学亚型的可靶向变异分布

Molecular Profiling Across 80,000 Patients With Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2026-03-26

该研究对82,328例经组织学确诊的NSCLC患者行综合基因组分析,发现35.1%存在可靶向基因变异,肺腺癌和腺鳞癌频率最高,肉瘤样癌METex14跳跃突变频率最高,支持所有NSCLC亚型均应进行分子检测。

要点

  • 35.1%的NSCLC患者携带可靶向基因变异,肺腺癌和腺鳞癌频率最高。
  • 肉瘤样癌METex14跳跃突变频率达9.95%,高于肺腺癌的2.43%。
  • 可靶向变异患者通常肿瘤突变负荷较低(80.88%)。

核心结论

  • 在82,328例NSCLC中,35.1%存在可靶向基因变异,且各组织学亚型均有足够频率,支持所有NSCLC病例均应考虑分子检测。

研究设计与样本

  • 观察性回顾性分析,纳入2014至2022年经组织学确诊的NSCLC病例,使用Foundation One/Foundation CDx行综合基因组分析,共82,328例。

主要发现

  • 可靶向基因变异总体频率为35.1%,肺腺癌45.8%、腺鳞癌40.9%、肉瘤样癌29.1%、非特指型27.6%、大细胞癌21.1%、鳞状细胞癌6.5%。
  • 肉瘤样癌METex14跳跃突变频率为9.95%,肺腺癌为2.43%。
  • 肿瘤突变负荷≥10 mut/Mb在大细胞癌为50.91%、非特指型40.79%、鳞状细胞癌39.08%、肉瘤样癌36.30%、肺腺癌31.22%、腺鳞癌29.22%。
  • 可靶向基因变异患者中80.88%肿瘤突变负荷较低。
  • 年龄与BRAF/ERBB2突变、ALK/RET/ROS1重排及MET扩增显著相关(p<0.005);EGFR可靶向突变和KRAS G12C在女性中更常见;EGFR可靶向突变与南亚/东亚及美洲遗传祖先强相关。

临床怎么用

  • 所有NSCLC组织学亚型均应考虑行全面分子检测,不应仅局限于肺腺癌。

局限性

  • 本文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biomarker testing is an essential component of optimal therapeutic management in NSCLC, enabling the use of both Food and Drug Administration-approved and emerging targeted therapies. Despite well-established biomarker testing guidelines and the availability of many approved targeted therapies, a substantial proportion of patients with advanced NSCLC are not benefiting from precision oncology. In this study, we analyze the distribution of actionable genomic alterations across histologic subtypes and clinicodemographic subgroups of NSCLC using data in 82,328 samples profiled with a single comprehensive genomic profiling assay, aiming to support universal molecular testing across all NSCLC subtypes to ensure equitable access to available therapeutics. METHODS: This is an observational retrospective analysis on histologically confirmed NSCLC cases tested with comprehensive genomic profiling by next-generation sequencing between 2014 and 2022 using Foundation One/Foundation CDx. All cases were centrally reviewed by board-certified anatomic pathologist to determine histologic type and subtype. RESULTS: A total of 82,328 patients with NSCLC were included. An actionable genomic alteration (GA) was found in 35.1% of the cases. Lung adenocarcinoma (LUAD) and adenosquamous carcinoma were more frequently associated with actionable GA (45.8% and 40.9%, respectively) as compared with sarcomatoid (29.1%), not otherwise specified (27.6%), large cell (21.1%), and squamous cell (6.5%) histologies. Sarcomatoid histology had the highest METex14 skipping mutation (mut) frequency (9.95% versus 2.43% in LUAD). Tumor mutation burden more than or equal to 10 mut/Mb was associated with histology (50.91% in large cell, 40.79% in not otherwise specified, 39.08% in squamous cell, and 36.30% in sarcomatoid versus 31.22% in LUAD and 29.22% in adenosquamous carcinoma). Patients with actionable GA had usually a low tumor mutation burden (80.88%). A significant correlation (p < 0.005) between age and actionable GA was reported for BRAF/ERBB2 muts, ALK/RET/ROS1 rearrangements, and MET amplification. EGFR actionable muts and KRAS G12C were more frequently observed in females, whereas no significant correlation between sex and other GA was observed. Finally, genetic ancestry analyses revealed a strong correlation for EGFR actionable muts and South/East Asia and America, but not for other GA. CONCLUSIONS: This is the largest NSCLC data set analyzed for biomarker distribution across histologies, age, sex, and genetic ancestry. This data set confirms sufficient enough biomarker prevalence across many histologic subtypes of NSCLC, providing reassurance that all NSCLC cases should be considered for biomarker workup.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Russo A, Javey M, Huang RSP, et al. Molecular Profiling Across 80,000 Patients With Lung Cancer. J Thorac Oncol. 2026. PMID: 41903702. doi:10.1016/j.jtho.2026.103695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。